Kenneth J. Kelley, Director at HALOZYME THERAPEUTICS INC (HTI), sold 12,500 shares at $10.55 ($130K) on 2007-05-07, disclosed to the SEC on 2007-05-09.
Scheduled sale ($130k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.35 | 300 | $3K | 2.4% |
| 2 | $10.36 | 400 | $4K | 3.2% |
| 3 | $10.37 | 200 | $2K | 1.6% |
| 4 | $10.38 | 3,076 | $32K | 24.6% |
| 5 | $10.39 | 2,900 | $30K | 23.2% |
| 6 | $10.40 | 2,000 |
| $21K |
| 16.0% |
| 7 | $10.41 | 224 | $2K | 1.8% |
| 8 | $10.42 | 900 | $9K | 7.2% |
| 9 | $10.43 | 500 | $5K | 4.0% |
| 10 | $10.44 | 200 | $2K | 1.6% |
| 11 | $10.45 | 1,500 | $16K | 12.1% |
| 12 | $10.50 | 200 | $2K | 1.6% |
| 13 | $10.55 | 100 | $1K | 0.8% |
| Total | $10.40 avg | 12,500 | $130K | 100% |
| Filing → |
| HALO | SELL | 2021-02-01 | $469K | — | Filing → |
| HALO | SELL | 2021-01-04 | $417K | — | Filing → |
| HALO | SELL | 2020-12-07 | $1.4M | — | Filing → |